梅克尔细胞癌
提吉特
封锁
彭布罗利珠单抗
癌症研究
细胞毒性T细胞
免疫疗法
CD8型
T细胞
癌
医学
梅克尔多元癌细胞病毒
T细胞受体
免疫学
内科学
抗原
生物
免疫系统
受体
体外
生物化学
作者
Scott Lien,Dalam Ly,S.Y. Cindy Yang,Ben X. Wang,Derek Clouthier,Michael St. Paul,Ramy Gadalla,Babak Noamani,Carlos R. Garcia-Batres,Sarah Boross-Harmer,Philippe L. Bédard,Trevor J. Pugh,Anna Spreafico,Naoto Hirano,Albiruni R. Abdul Razak,Pamela S. Ohashi
标识
DOI:10.1038/s41467-024-45449-y
摘要
Abstract Immunotherapies targeting PD-1/PD-L1 are now widely used in the clinic to treat a variety of malignancies. While most of the research on T cell exhaustion and PD-1 blockade has been focused on conventional αβ T cells, the contribution of innate-like T cells such as γδ T cells to anti-PD-1/PD-L1 mediated therapy is limited. Here we show that tumor reactive γδ T cells respond to PD-1 blockade in a Merkel cell carcinoma (MCC) patient experiencing a complete response to therapy. We find clonally expanded γδ T cells in the blood and tumor after pembrolizumab treatment, and this Vγ2Vδ1 clonotype recognizes Merkel cancer cells in a TCR-dependent manner. Notably, the intra-tumoral γδ T cells in the MCC patient are characterized by higher expression of PD-1 and TIGIT, relative to conventional CD4 and CD8 T cells. Our results demonstrate that innate-like T cells could also contribute to an anti-tumor response after PD-1 blockade.
科研通智能强力驱动
Strongly Powered by AbleSci AI